Anavex Life Sciences Corp (AVXL)

[F1ash]

“Patients Treated with Higher ANAVEX®2-73 Concentration Show Higher MMSE* Performance Compared to Lower Concentration


High Concentration cohort shows 64 % less decline than low concentration cohort


“High plasma concentration of ANAVEX®2-73 [>4.0 ng/ml] is correlated with the clinically administered dose



Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity and reversible.



75 neurological AE’s at 57 weeks and only 13 at 148 weeks.


“Nearly all patients (98%) had some sort of adverse event, but most of them were mild transitory dizziness or headache; 76% of the events were grade 1, and 2% were grade 2. There were no serious adverse events. Three subjects dropped out because of adverse events (delirium, dizziness, and a combination of confusion, disorientation, and lethargy)”


followed by an 11-day washout period, and then 30 or 50 mg/day oral ANAVEX 2-73 for 11 days. This was followed by a 52-week, open-label, extension trial of 10-50 mg/day orally, titrating each patient to the maximum tolerated dose. “

76 + 2 = 78


https://www.mdedge.com/neurology/article/120066/alzheimers-cognition/sigma-1-agonist-presses-forward-after-positive-results



https://www.anavex.com/wp-content/uploads/2019/03/Anavex-Presentation-March-2019-1.pdf